𝔖 Bobbio Scriptorium
✦   LIBER   ✦

p16INK4a expression in cytology of ascites and response to chemotherapy in advanced ovarian cancer

✍ Scribed by Tomoko Goto; Masashi Takano; Junko Hirata; Toshiyuki Kohno; Shigenori Ohtsuka; Keiichi Fujiwara; Hitoshi Tsuda

Publisher
John Wiley and Sons
Year
2009
Tongue
French
Weight
313 KB
Volume
125
Category
Article
ISSN
0020-7136

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

The aim of this study is to investigate p16INK4a expression by immunocytochemistry for ascites in advanced ovarian cancer and explore the possibility to predict chemotherapeutic response and prognosis. The immunocytochemical study was performed on cytology of ascites obtained from 37 Stage III or Stage IV ovarian cancer patients with measurable disease before platinum/taxane‐based first‐line chemotherapy following primary cytoreductive surgery or as neoadjuvant chemotherapy. Twenty‐one of 21 (100%) responders and 6 of 16 (44%) nonresponders showed p16INK4a immunopositivity (p < 0.001). Immunopositivity was frequently observed in serous adenocarciomas (17 of 18, 94%). Overall survival was significantly better in immunopositive cases compared with immunonegative cases (p = 0.0006). For subcellular localization, cytoplasm was diffusely positive in immunopositive cases (n = 27), 12 of which showed stronger nuclear immunostaining and demonstrated superior overall survival. In vitro expression of p16INK4a protein was also examined for both parent chemosensitive and acquired chemoresistant ovarian cancer cell lines. Chemosensitive KF28 parent cells showed stronger nuclear staining compared with chemoresistant KFr13Tx cells showing stronger cytoplasmic staining by immunocytochemistry, which were also confirmed by western blotting. Our data suggest that p16INK4a expression in cytology of ascites is a candidate marker in prediction of the primary response to chemotherapy and prognosis. Β© 2009 UICC

πŸ“œ SIMILAR VOLUMES

Alterations of the p16INK4A gene in huma
Alterations of the p16INK4A gene in human ovarian cancers
✍ Tatsuya Kanuma; Jun-ichi Nishida; Tomonao Gima; J. Carl Barrett; Norio Wake πŸ“‚ Article πŸ“… 1997 πŸ› John Wiley and Sons 🌐 English βš– 394 KB πŸ‘ 1 views

The p16 INK4A gene, which encodes the cell-cycle regulatory protein cyclin-dependent kinase 4 inhibitor, is a putative tumor-suppressor gene. We examined p16 gene alterations in 30 primary ovarian cancers and 11 ovarian cancer cell lines. Five of the primary cancers (16.7%) had lost both p16 INK4A g

p53 and PCNA expression in advanced colo
p53 and PCNA expression in advanced colorectal cancer: Response to chemotherapy and long-term prognosis
✍ Angelo Paradiso; Mario Rabinovich; Carlos Vallejo; Mario Machiavelli; Alberto Ro πŸ“‚ Article πŸ“… 1996 πŸ› John Wiley and Sons 🌐 French βš– 660 KB

In a series of 71 patients with advanced colorectal cancer treated with biochemically modulated 5-fluorouracil(5-FU) and methotrexate (MTX), we investigated the relationship between the proliferating-cell nuclear antigen (PCNA) (PC 10) and p53 (Pab I80 I) primary-tumor immunohistochemical expression

Inactivation of p16/CDKN2 and p15/MTS2 i
Inactivation of p16/CDKN2 and p15/MTS2 is associated with prognosis and response to chemotherapy in ovarian cancer
✍ Kazuya Kudoh; Yoshihito Ichikawa; Sadao Yoshida; Misako Hirai; Yoshihiro Kikuchi πŸ“‚ Article πŸ“… 2002 πŸ› John Wiley and Sons 🌐 French βš– 130 KB

## Abstract To define the involvement of __p16/CDKN2__ and __p15/MTS2__ tumor‐suppressor genes for response to chemotherapy in primary epithelial ovarian cancer, we analyzed alterations of the gene in 45 patients who were treated with primary cytoreductive surgery followed by 6 courses of cis‐diamm